Orchard Therapeutics 11% in premarket on moderate volume, after a positive CHMP opinion recommending approval of Libmeldy, an investigational gene therapy for the treatment of metachromatic leukodystrophy (MLD), a rare genetic condition caused by mutations in the ARSA gene, characterized by accumulation of fats called sulfatides, which causes the destruction of the protective fatty layer surrounding the nerves in both the central and the peripheral nervous system. Source: Seeking Alpha 16/10/2020